NFE2L2 and non-small cell lung carcinoma: On the one hand, these patients were not eligible for targeting treatments because of the lack of activating genetic mutations or fusions and the resistance to the kinase inhibitor drugs,53 on the other hand, previous studies had demonstrated that the genetic alterations on the NFE2L2 pathway's gene would result in tumor resistances against chemotherapeutic agents in NSCLC.37, 54, 55